false

Chris Ingram

Chris Ingram, BSc (Hons) is Head of Regulatory Consultancy (Europe) for Precision for Medicine. Chris received his BSc(Hons) in immunology and pharmacology from the University of Strathclyde and has since spent over 21 years working in regulatory affairs with a focus on clinical development. Chris’ regulatory expertise covers clinical development across all phases, regulatory strategy, marketing authorisations, scientific advice, orphan drug designation and paediatric investigation plans across a wide variety of therapeutic areas, including but not limited to, oncology, CNS, metabolic, endocrinology, analgesia and cardiovascular.

• Read: Navigating Site Activation Strategy Under the EU Clinical Trials Regulation

  Regulatory

  Navigating Site Activation Strategy Under the EU Clinical Trials Regulation

  May 29, ‘24 | 7 min read

  • 

    Barbara K.

  • 

    Chris I.

  Discover
• Read: The 10 Proposed Revisions to UK Clinical Trial Regulations

  Regulatory

  The 10 Proposed Revisions to UK Clinical Trial Regulations

  Feb 15, ‘22 | 6 min read

  • 

    Chris Ingram

  Discover
• Read: Proposed Legislative Changes for UK Clinical Trials

  Regulatory

  Proposed Legislative Changes for UK Clinical Trials

  Feb 04, ‘22 | 2 min read

  • 

    Chris Ingram

  Discover
• Read: Implications of EU-CTR Regulation 536/2014

  Clinical Trials - Regulatory

  Implications of EU-CTR Regulation 536/2014

  Nov 30, ‘21 | 3 min read

  • 

    Chris Ingram

  Discover
• Read: BREXIT: What has Changed in the United Kingdom Clinical Trial Regulatory Landscape?

  Regulatory

  BREXIT: What has Changed in the United Kingdom Clinical Trial Regulatory Landscape?

  Sep 16, ‘21 | 3 min read

  • 

    Chris Ingram

  Discover

Loading...

You've reach the end Back to top